Thompson Travis Alvin 4

What Happened
Travis Alvin Thompson, Chief Financial Officer of Bicycle Therapeutics plc (BCYC), received a derivative award (reported as transaction code A) for 60,000 shares on July 15, 2026. The Form 4 lists the acquisition price as $0.00, indicating this is an equity award (e.g., stock options or similar), not an open‑market purchase or sale. The award vests over a four‑year schedule (see footnote).

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely filing).
• Transaction type/code: Grant/Award (A), derivative security.
• Shares/units granted: 60,000; price reported: $0.00 (no cash paid at grant in Form 4).
• Vesting (footnote): 1/4 of the award vests on July 15, 2027, then the remainder vests in 36 equal monthly installments.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• No indication in the filing that shares were immediately sold or that tax withholding/10b5-1 plan applied.

Context
This is a compensation award to an executive, not an open‑market purchase or sale — such grants are common for retention and long‑term incentive purposes and vest over time, so they do not represent an immediate change in tradable holdings. For retail investors, grants signal management stake alignment over the vesting period but do not necessarily indicate near‑term bullish or bearish intent.